| Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma: a systematic review and network meta-analysis CY Chang, H Park, DC Malone, CY Wang, DL Wilson, YM Yeh, ... JAMA network open 3 (3), e201611-e201611, 2020 | 86 | 2020 |
| Central nervous system effects of oral propranolol for infantile hemangioma: a systematic review and meta-analysis T Thai, CY Wang, CY Chang, JD Brown Journal of Clinical Medicine 8 (2), 268, 2019 | 25 | 2019 |
| A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan V Diaby, H Alqhtani, S van Boemmel-Wegmann, CY Wang, AA Ali, ... The Breast 49, 141-148, 2020 | 13 | 2020 |
| Trends in use of granulocyte colony-stimulating factor following introduction of biosimilars among adults with cancer and commercial or Medicare insurance from 2014 to 2019 CY Wang, CD Heldermon, SM Vouri, H Park, SE Wheeler, ... JAMA Network Open 4 (11), e2133474-e2133474, 2021 | 9 | 2021 |
| Using time series analysis to forecast the health-related quality of life of post-menopausal women with non-metastatic ER+ breast cancer: a tutorial and case study H Xiao, X Jiang, C Chen, W Wang, CY Wang, AA Ali, A Berthe, ... Research in Social and Administrative Pharmacy 16 (8), 1095-1099, 2020 | 8 | 2020 |
| Predicting cost‐effectiveness of generic vs. brand dabigatran using pharmacometric estimates among patients with atrial fibrillation in the United States CY Wang, PN Pham, S Kim, K Lingineni, S Schmidt, V Diaby, J Brown Clinical and Translational Science 13 (2), 352-361, 2020 | 6 | 2020 |
| Updating the cost effectiveness of oral anticoagulants for patients with atrial fibrillation based on varying stroke and bleed risk profiles CY Wang, PN Pham, TN Thai, JD Brown Pharmacoeconomics 38, 1333-1343, 2020 | 4 | 2020 |
| Readmissions after pancreatic surgery in patients with pancreatic cancer: does hospital variation exist for quality measurement? CY Wang, J Brown Visceral Medicine 36 (4), 304-311, 2020 | 4 | 2020 |
| Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured … CY Wang, H Park, CD Heldermon, SM Vouri, JD Brown Journal of Managed Care & Specialty Pharmacy 28 (7), 795-802, 2022 | 3 | 2022 |
| Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: A retrospective cohort study CY Wang, SM Vouri, H Park, CD Heldermon, JD Brown Journal of Managed Care & Specialty Pharmacy 29 (2), 119-127, 2023 | 2 | 2023 |
| Uncontrolled extensions of clinical trials and the use of external controls—scoping opportunities and methods CY Wang, JA Berlin, B Gertz, K Davis, J Li, NA Dreyer, W Zhou, ... Clinical Pharmacology & Therapeutics 111 (1), 187-199, 2022 | 2 | 2022 |
| Three-Year, Postintervention, Follow-up Comparison of Health Care Resource Utilization and Costs in the Lifestyle Interventions and Independence for Elders (LIFE) Study JD Brown, CY Wang, EJ Groessl, M Pahor, TM Manini The Journals of Gerontology: Series A 76 (2), 272-276, 2021 | 1 | 2021 |
| Dataset used in the economic evaluation trastuzumab-based regimens for HER-2 positive metastatic breast cancer patients in the Taiwanese healthcare setting V Diaby, CY Wang, H Alqhtani, S van Boemmel-Wegmann, AA Ali, ... Data in brief 29, 105194, 2020 | 1 | 2020 |
| Changes in medication use before and after bariatric surgery in older adults SM Vouri, CY Wang, L Hochleitner PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 126-127, 2022 | | 2022 |
| Use of a rate-based sequence symmetry analysis to assess recurring adverse drug events E Morris, CY Wang, J Antonelli, A Winterstein, J Hallas, SM Vouri PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 445-446, 2022 | | 2022 |
| EE423 Lower out-of-Pocket Costs Associated with Pegfilgrastim Biosimilars CY Wang, SM Vouri, H Park, CD Heldermon, JD Brown Value in Health 25 (7), S418, 2022 | | 2022 |
| P74 Real-World Comparative Effectiveness of Pegfilgrastim Biosimilars Versus Originator CY Wang, H Park, CD Heldermon, SM Vouri, JD Brown Value in Health 25 (7), S303, 2022 | | 2022 |
| Frequency and characteristics of uncontrolled long-term extensions to randomized controlled trials CY Wang, J Gretenkord, JD Seeger, KJ Davis, MR Iannacone, W Zhou, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 29, 373-373, 2020 | | 2020 |
| PCN93 A COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB-CONTAINING TREATMENT SEQUENCES FOR HER-2 POSITIVE METASTATIC BREAST CANCER PATIENTS IN TAIWAN V Diaby, H Alqhtani, S van Boemmel-Wegmann, CY Wang, AA Ali, ... Value in Health 23, S40, 2020 | | 2020 |
| Predicting Cost-Effectiveness of Generic Versus Brand Dabigatran Using Pharmacometric Estimates among Patients with Atrial Fibrillation in the United States CY Wang, PN Pham, S Kim, K Lingineni, S Schmidt, V Diaby, J Brown medRxiv, 19006346, 2019 | | 2019 |
